Leuprorelin Drugs Market Report 2026

The leuprorelin drugs market size has grown strongly in recent years. It will grow from $2.88 billion in 2025 to $3.07 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to limited availability of long-acting leuprorelin formulations, reliance on hospital-based administration, increasing prevalence of prostate cancer and endometriosis, growing awareness of hormone regulation therapies, adoption of monthly and short-term depot injections.

The leuprorelin drugs market size is expected to see strong growth in the next few years. It will grow to $3.95 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to development of extended-release implants and tablets, expansion of home care and specialty clinic administration, increasing pediatric hormonal therapy adoption, rising use of combination hormone therapy, integration of digital monitoring for treatment adherence. Major trends in the forecast period include rising adoption of depot injections and long-acting implants, growing awareness of hormonal therapies for prostate cancer and endometriosis, expansion of pediatric hormonal treatment programs, integration of subcutaneous and ready-to-use formulations, increased focus on home care and specialty clinic-based administration.

The rising prevalence of prostate cancer is expected to drive the growth of the leuprorelin drugs market in the coming years. Prostate cancer is a type of cancer that develops in the prostate gland, located below the bladder and in front of the rectum in men. The increase in cases is largely linked to the aging population, as the risk of developing prostate cancer rises significantly with age. Leuprorelin drugs aid in treatment by regulating hormone levels and slowing tumor growth, improving patient outcomes through consistent dosing, reducing cancer progression, and enhancing quality of life. For example, in January 2025, Prostate Cancer UK reported that prostate cancer diagnoses in England rose from 50,751 cases in 2022 to 55,033 cases in 2023, highlighting a clear increase in annual incidence. Thus, the growing prevalence of prostate cancer is fueling demand for leuprorelin drugs.

The rising demand for in vitro fertilization (IVF) treatments is also expected to boost the leuprorelin drugs market. IVF involves combining an egg and sperm outside the body in a laboratory to create an embryo, which is then transferred into the uterus to achieve pregnancy. Demand for IVF is increasing due to delayed parenthood, which contributes to age-related infertility and greater reliance on assisted reproductive methods. Leuprorelin drugs play a critical role in IVF by supporting controlled ovarian stimulation and cycle regulation, suppressing premature ovulation, and optimizing timing for successful procedures. For instance, in April 2025, the American Society for Reproductive Medicine reported that births resulting from IVF in the United States rose from 91,771 in 2022 to 95,860 in 2023, accounting for 2.6% of all births. IVF cycles also increased from 389,993 in 2022 to 432,641 in 2023 across 371 reporting SART clinics. Therefore, the growing demand for IVF treatments is contributing to the expansion of the leuprorelin drugs market.

Major companies in the leuprorelin drugs market are focusing on advanced formulations such as ready-to-use injections to improve convenience, enhance adherence, and reduce preparation errors. Ready-to-use injections are pre-filled, sterile formulations of leuprolide acetate that eliminate the need for reconstitution, simplifying administration for both healthcare providers and patients. For example, in June 2025, Avenacy Inc., a US-based biopharmaceutical company, launched a leuprolide acetate injection, a synthetic hormone therapy primarily used for the palliative treatment of advanced prostate cancer. This formulation provides a reliable and convenient treatment option, reduces the risk of dosing errors and contamination, and ensures consistent therapeutic efficacy. As a gonadotropin-releasing hormone (GnRH) agonist, it initially increases and then significantly reduces testosterone levels, helping to slow the growth of hormone-sensitive cancer cells.

Major companies operating in the leuprorelin drugs market are Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Limited, Lupin Limited, Livzon Pharmaceutical Group Inc., Alkem Laboratories Limited, Daewoong Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Gland Pharma Limited, Tolmar Pharmaceuticals Inc., Beijing Biote Pharmaceutical Co. Ltd., Accord Healthcare Limited, Intas Pharmaceuticals Limited, Foresee Pharmaceuticals Co Ltd., Samarth Life Sciences Private Limited.

North America was the largest region in the leuprorelin drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leuprorelin drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leuprorelin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the leuprorelin drugs market by increasing costs of imported biologics, polymer implants, and pre-filled injection systems. Segments such as long-acting depot injections and biodegradable implants are most affected, particularly in North America and Europe, which rely heavily on imports. This has led to higher treatment costs and potential supply delays. On the positive side, tariffs have encouraged local manufacturing, innovation in implant and injection delivery systems, and investment in domestic pharmaceutical production capacities.

The leuprorelin drugs market research report is one of a series of new reports that provides leuprorelin drugs market statistics, including leuprorelin drugs industry global market size, regional shares, competitors with a leuprorelin drugs market share, detailed leuprorelin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the leuprorelin drugs industry. This leuprorelin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leuprorelin drugs are synthetic gonadotropin-releasing hormone (GnRH) agonists used to reduce the production of sex hormones. They function by initially stimulating and then downregulating the pituitary gland’s secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in decreased production of sex hormones such as testosterone and estrogen. This hormonal regulation significantly lowers the body’s natural hormone levels, making leuprorelin drugs useful in a variety of medical conditions.

The main types of leuprorelin drugs include injections, tablets, and implants. Leuprorelin injections, which contain leuprorelin acetate, are administered subcutaneously or intramuscularly to suppress sex hormone production and are used in treating prostate cancer, endometriosis, breast cancer, and central precocious puberty. These injections are available in different formats, including depot injections and ready-to-use formulations, and are administered via intramuscular or subcutaneous routes. Leuprorelin drugs are applied in conditions such as advanced prostate cancer, uterine fibroids, endometriosis, and early puberty, serving a range of end users including hospitals, specialty clinics, and home care settings.

The leuprorelin drugs market consists of sales of products including depot formulations, microparticle suspension, prefilled syringes, and leuprolide acetate kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.